DXCM News and Press, DexCom Inc. From 10/28/22

DexCom ( NASDAQ: DXCM ) climbed ~16% intraday Friday to reach the highest level since April after the medical device maker posted better-than- expected financials for Q3 2022, drawing favorable views on Wall Street. After the results, the analysts from Baird, Wells F...

Shares of DexCom (NASDAQ: DXCM) were trading up by 13.9% as of 11:55 a.m. ET Friday. The big gain came after the diabetes-care technology company announced its third-quarter results following the market close on Thursday. DexCom reported Q3 revenue of $769.6 million, up 18% year...

Image source: The Motley Fool. DexCom (NASDAQ: DXCM) Q3 2022 Earnings Call Oct 27, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: DexCom (DXCM) Q3 2022 Earnings Call Transcript

DexCom, Inc. (DXCM) Q3 2022 Earnings Conference Call October 27, 2022, 04:30 PM ET Company Participants Sean Christensen - IR Kevin Sayer - Chairman, President and CEO Jereme Sylvain - CFO Jake Leach - COO Conference Call Participants Jeff Johnson...

DexCom ( NASDAQ: DXCM ) is up 6% in post-market trading after posting Q3 2022 financial results that beat on the top and bottom lines . Net income in the quarter increased ~16% to ~$101M compared to the prior-year period ($0.24 vs, $0.21 diluted net income per shar...

DexCom press release ( NASDAQ: DXCM ): Q3 Non-GAAP EPS of $0.28 beats by $0.04 . Revenue of $769.6M (+18.4% Y/Y) beats by $18.56M . 2022 Guidance: Revenue of approximately $2.88 - 2.91 billion (18-19% reported growth) Non-GAAP Gross Profit Margin of ap...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights: Revenue grew 18% versus the same quarter of the prior year to $769.6 million on a reported basis and 20% on an orga...

DexCom ( NASDAQ: DXCM ) is scheduled to announce Q3 earnings results on Thursday, October 27th, after market close. The consensus EPS Estimate is $0.24 (-73.0% Y/Y) and the consensus Revenue Estimate is $751.04M (+15.5% Y/Y). Over the last 2 years, DXCM has beaten EP...

Dubbed “Dexcom U,” the multi-year program’s inaugural roster consists of 14 athletes with diabetes across 11 sports Program aims to offer greater representation for people with diabetes in sports and inspiration to aspiring athletes with diabetes ...

Summary Baxter International has had a rough year or so, with shares declining far more than the market has. Some of this was justified by the company's high share price and weakening fundamentals. But given where shares are today, the firm does seem to offer some upside for i...